Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
IPO Year:
Exchange: NASDAQ
Website: baudaxbio.com
SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G - Baudax Bio, Inc. (0001780097) (Subject)
SC 13G - Baudax Bio, Inc. (0001780097) (Subject)
8-K - Baudax Bio, Inc. (0001780097) (Filer)
25-NSE - Baudax Bio, Inc. (0001780097) (Subject)
8-K - Baudax Bio, Inc. (0001780097) (Filer)
424B3 - Baudax Bio, Inc. (0001780097) (Filer)
10-Q - Baudax Bio, Inc. (0001780097) (Filer)
NT 10-Q - Baudax Bio, Inc. (0001780097) (Filer)
8-K - Baudax Bio, Inc. (0001780097) (Filer)
8-K - Baudax Bio, Inc. (0001780097) (Filer)
8-K - Baudax Bio, Inc. (0001780097) (Filer)
DEFA14A - Baudax Bio, Inc. (0001780097) (Filer)
3 - Baudax Bio, Inc. (0001780097) (Issuer)
3 - Baudax Bio, Inc. (0001780097) (Issuer)
4 - Baudax Bio, Inc. (0001780097) (Issuer)
4 - Baudax Bio, Inc. (0001780097) (Issuer)
4 - Baudax Bio, Inc. (0001780097) (Issuer)
4 - Baudax Bio, Inc. (0001780097) (Issuer)
4 - Baudax Bio, Inc. (0001780097) (Issuer)
4 - Baudax Bio, Inc. (0001780097) (Issuer)
4 - Baudax Bio, Inc. (0001780097) (Issuer)
4 - Baudax Bio, Inc. (0001780097) (Issuer)
MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distri
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) ("Baudax Bio" or the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, today announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases. "This combination blends the world class scientific expertise of the TeraImmune team with
MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the "Annual Meeting") without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m. Eastern time on June 23, 2023 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2023. The record date for determining shareholders eligible to vote at the Special Meeting will remain the close of business
MALVERN, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on September 29, 2022. The shares of Series B Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 3, 2022. The outstanding shares of Series B Preferred Stock will vote together with the outsta
MALVERN, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has adjourned its 2022 Annual Meeting of Shareholders (the "Annual Meeting"), without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m. Eastern time on May 18, 2022 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2022. The record date for determining shareholders eligible to vote at the Annual Meeting will remain the close of business on March 29
MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. Baudax Bio will host a conference call and webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and recent operational highlights. To access the conference call, please dial (866) 220-5595 (local) or (615) 622-8062 (international) at least 10 minutes prior to the start time and refer to conference ID 1078117. A live audio webcast of the call will be available under "Events" in the Investor section of the
ANJESO® Revenue Up 40% in Q3 2021 over Q2 2021 and Up Over 300% in Q3 2021 over Q3 2020 Solid Growth in End User Demand Units, September 2021 Strongest Month Launch-to-Date, Indicating Growing Adoption of ANJESO Neuromuscular Blocking Agent BX1000 Completes Clinical Phase of Dose Escalation Study Management to Host Investor Conference Call and Webcast Today at 8:00 a.m. ET MALVERN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today reported financial results for the three and nine months ended September 30, 2021, and provided key metr
MALVERN, Pa., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021. Baudax Bio's management team will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021 to discuss the financial results and recent operational highlights. To access the conference call please dial (866) 220-5595 (local) or (615) 622-8062 (international) at least 10 minutes prior to the start time and refer to conference ID 9972669. A live audio webcast of the call wi
MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, recently announced that it has adjourned its Special Meeting of Shareholders (the "Special Meeting") solely with respect to Proposal 1 set forth in its Definitive Proxy Statement ("Proxy Statement") filed with the Securities and Exchange Commission on June 14, 2021. Proposal 1 is a proposal to amend the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Company had adjou
Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024 MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that following recent shareholder approval of corporate actions related to
MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company's next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.
MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that that the Company's management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023 in New York, NY. Gerri Henwood, President & Chief Executive Officer of Baudax Bio, will give a pre-recorded presentation highlighting the Company's cellular therapy progra
MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distri
MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, today announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and 1,395,243 Series E pre-funded warrants at a purchase price of $0.56 per share of common stock (or $0.55 per prefunded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private pla
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace Announcement of Positive Top-Line Results from Phase 2 BX1000 Trial MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) ("Baudax Bio" or the "Company"), is a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced results for the three and six
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) ("Baudax Bio" or the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, today announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases. "This combination blends the world class scientific expertise of the TeraImmune team with
MALVERN, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, today announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium. The BX1000 Phase 2 surgery trial was a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in
MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the "Annual Meeting") without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m. Eastern time on June 23, 2023 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2023. The record date for determining shareholders eligible to vote at the Special Meeting will remain the close of business
Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio Secured $4 Million in Gross Proceeds from Public Offering in May MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update. "During the first quarter we made significant progress advancing our neuromuscular blocking agent (NMB) portfolio, announcing positive top
Experienced financial executive will build on growth trajectory Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005044/en/Rick Casten, SVP and Chief Financial Officer, Cosette Pharmaceuticals (Photo: Business Wire) "I am excited to have Rick Casten join our team, with his more than two decades of experience in helping drive long term performance gains and financial growth. Rick joins Cosette at a pivotal inflection point
MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products and public accounting. He replaces Ryan D. Lake, CPA who is transitioning to full time Chief Financial Officer for Recro. “I am delighted to welcome Richard to the Baudax team and believe his expertise and leadersh